Inactive Instrument

Metacrine, Inc.

MTCR

US59101E1038

Biotechnology & Medical Research

Metacrine, Inc. Announces Resignation of Trisha Millican as Chief Financial Officer

February 24, 2022 at 09:05 pm

Metacrine, Inc. announced Ms. Trisha Millican resigned as chief financial officer. Ms. Millican will remain with the company until March 31, 2022 to ensure smooth transition.

Latest news about Metacrine, Inc.

Metacrine, Inc. Announces Board Changes	23/03/23	CI
Metacrine, Inc. Announces CEO Changes	23/03/23	CI
Metacrine, Inc.(OTCPK:MTCR) dropped from S&P TMI Index	13/02/23	CI
Metacrine, Inc.(OTCPK:MTCR) dropped from NASDAQ Composite Index	08/02/23	CI
Metacrine, Inc. Appoints Michael York as President	03/02/23	CI
Metacrine, Inc. Appoints Michael York as Chief Executive Officer	03/02/23	CI
Insider Sell: Metacrine	27/01/23	MT
North American Morning Briefing : China Optimism Gives Boost to Futures	27/12/22	DJ
Equillium, Metacrine Agree to Terminate Proposed Merger	27/12/22	MT
Metacrine, Equillium Mutually Agree to Terminate Merger Accord	23/12/22	MT
Equillium, Inc. (NasdaqGM:EQ) cancelled the acquisition of Metacrine, Inc. from a group of shareholders.	22/12/22	CI
Insider Buy: Metacrine	21/12/22	MT
Metacrine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Insider Buy: Metacrine	31/10/22	MT
Metacrine, Inc. Enters into A License Agreement with FL2022-001, Inc	11/10/22	CI
Health Care Up as Investors Rotate Back into Bull-Market Leaders -- Health Care Roundup	07/09/22	DJ
Transcript : Equillium, Inc., Metacrine, Inc. - M&A Call	07/09/22
Equillium to Acquire Biopharmaceutical Company Metacrine in All-Stock Deal	06/09/22	MT
Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. from a group of shareholders.	05/09/22	CI
Metacrine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
Metacrine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
Metacrine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/03/22	CI
Metacrine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	30/03/22	CI
Metacrine, Inc. Enters into an Agreement for Termination of Lease	15/03/22	CI
Metacrine, Inc. Announces Patricia Millican to Retire as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Effective as of March 31, 2022	03/03/22	CI

Metacrine, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The Companyâs advanced program targets the farnesoid X receptor (FXR), which is central to modulating GI and liver diseases. The Companyâs pipeline includes MET642 and hydroxysteroid dehydrogenase 17B13 (HSD17B13 or HSD). MET642 is used for the treatment of inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohnâs disease. HSD17B13 is used for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). The Company has built a proprietary library of approximately 2,500 FXR compounds.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research

Metacrine, Inc.

Equities

MTCR

US59101E1038

Biotechnology & Medical Research

Metacrine, Inc. Announces Resignation of Trisha Millican as Chief Financial Officer

Latest news about Metacrine, Inc.

Chart Metacrine, Inc.

Company Profile

Sector Other Biotechnology & Medical Research